Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment - Concepedia

Concepedia

Publication | Closed Access

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

135

Citations

22

References

2013

Year

Sushil K. Badrising, Vincent van der Noort, Inge M. van Oort, H. Pieter van den Berg, Maartje Los, Paul Hamberg, Jules L.L.M. Coenen, Alfons J.M. van den Eertwegh, Igle J. de Jong, Emile D. Kerver,

Abstract

Enz has modest clinical activity in patients with metastatic, castrate-resistant prostate cancer who previously received Doc and AA. PSA response to Doc and AA does not predict for PSA response to ENz.

References

	Year	Citations

Page 1